ACM
IART icon

Aubrey Capital Management’s Integra LifeSciences IART Stock Holding History

Aubrey Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,405
Closed -$78.8K – 50
2022
Q4 		$78.8K Hold
1,405
– – 0.06% 48
2022
Q3 		$59.5K Hold
1,405
– – 0.05% 49
2022
Q2 		$75.9K Buy
+1,405
New +$84.4K 0.06% 52
2022
Q1 		– Sell
-3,405
Closed -$228K – 70
2021
Q4 		$228K Buy
+3,405
New +$230K 0.09% 41

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aubrey Capital Management's IART Position: Q1 2023 in Review

Aubrey Capital Management sold out of Integra LifeSciences (IART) in Q1 2023, closing a stake of 1,405 shares — an estimated $78.8K sold.

Aubrey Capital Management first reported a position in IART in Q4 2021 and held it in 4 quarters. The position peaked at $228K in Q4 2021. 279 funds tracked by Wall St. Rank hold IART as of Q1 2023.

  • Aubrey Capital Management reported no remaining Integra LifeSciences position as of Q1 2023 after selling out during the quarter.
  • Aubrey Capital Management sold 1,405 Integra LifeSciences shares in Q1 2023, an estimated $78.8K.
  • Aubrey Capital Management first reported a position in Integra LifeSciences in Q4 2021 and held it in 4 quarters.
  • Aubrey Capital Management's Integra LifeSciences position peaked at $228K in Q4 2021.
  • 279 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2023.

Based on Aubrey Capital Management's 13F filing for Q1 2023, filed 24 Apr 2023.